| ITEM 5.08 | SHAREHOLDER DIRECTOR NOMINATIONS. |
The information set forth under Item 8.01 is incorporated by reference.
As previously disclosed, Zymeworks Inc. (“Zymeworks”) has proposed to carry out a series of transactions, including a corporate redomicile (the “Redomicile Transactions”). The Redomicile Transactions are subject to certain requirements and approvals, including approval by Zymeworks securityholders, as further described in the definitive proxy statement (the “Proxy Statement”) filed by Zymeworks with the Securities and Exchange Commission on September 2, 2022.
If the necessary approvals are obtained and other conditions to closing satisfied, then, following the closing of the Redomicile Transactions, Zymeworks will become a subsidiary of a new parent company, which is currently named Zymeworks Delaware Inc. (and which will be renamed Zymeworks Inc. in connection with the closing) (“New Zymeworks”). As a result of the Redomicile Transactions, all current Zymeworks shareholders will become stockholders of New Zymeworks or, at their election and subject to meeting eligibility criteria and an overall cap, shareholders of a subsidiary of New Zymeworks.
If the Redomicile Transactions are approved, Zymeworks expects that, in connection with the closing of the Redomicile Transactions, New Zymeworks will adopt amended and restated bylaws (the “Post-Redomicile Bylaws”) in substantially the form attached as Appendix G to the Proxy Statement. New Zymeworks also expects to hold an annual meeting of stockholders in the fourth quarter of 2022 (the “2022 Annual Meeting”), and that the Post-Redomicile Bylaws will govern the conduct of the 2022 Annual Meeting. The Post-Redomicile Bylaws set forth the procedures that must be followed by a stockholder who wishes to present a proposal (made other than pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 (the “Exchange Act”)) or nominate a director for election at an annual meeting. With respect to the 2022 Annual Meeting, to be timely (including for purposes of Rule 14a-4(c) of the Exchange Act), the Post-Redomicile Bylaws provide that a stockholder’s written notice of such proposal or nomination must be received:
| | • | | No earlier than 8:00 a.m., Eastern time, on September 23, 2022; and |
| | • | | No later than 5:00 p.m., Eastern time, on October 4, 2022. |
Such notice may be sent, in compliance with the procedures outlined in the Post-Redomicile Bylaws, to either Zymeworks’ corporate secretary at Suite 800, 114 East 4th Avenue, Vancouver, British Columbia, Canada V5T 1G4 or to New Zymeworks’ corporate secretary at 108 Patriot Drive, Suite A, Middletown, Delaware 19709.
In accordance with Rule 14a-5(f) of the Exchange Act, Zymeworks and New Zymeworks have both determined that proposals to be considered for inclusion in New Zymeworks’ proxy statement for the 2022 Annual Meeting pursuant to Rule 14a-8 of the Exchange Act must be received by Zymeworks’ corporate secretary or New Zymeworks’ corporate secretary (in each case at the address set forth above) no later than 5:00 p.m., Eastern time, on October 4, 2022 (the “Rule 14a-8 Deadline”).
Similarly, if the Redomicile Transactions are not completed, Zymeworks expects to hold the 2022 Annual Meeting in the fourth quarter of 2022 and has determined that for proposals to be considered for inclusion in Zymeworks’ proxy statement for the 2022 Annual Meeting pursuant to Rule 14a-8 of the Exchange Act, such proposals must be received by Zymeworks’ corporate secretary (at the address set forth above) no later than the Rule 14a-8 Deadline.
Important Information for Investors and Securityholders
This communication is not intended to and does not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, purchase, or exchange of securities or solicitation of any vote or approval in any jurisdiction in contravention of applicable law. In connection with the proposed Redomicile Transactions, Zymeworks has caused its subsidiary New Zymeworks, to file a registration statement on Form S-4 (the “Registration Statement”), which includes New Zymeworks’ prospectus as well as Zymeworks’ Proxy Statement (the “Proxy Statement/Prospectus”), with the U.S. Securities and Exchange Commission (the “SEC”) and the appropriate Canadian securities regulatory authorities. Zymeworks has mailed the Proxy Statement/Prospectus to its shareholders and holders of its warrants and outstanding equity awards in connection with the proposed Redomicile Transactions. INVESTORS AND SECURITYHOLDERS OF ZYMEWORKS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ZYMEWORKS, NEW ZYMEWORKS, THE REDOMICILE TRANSACTIONS, AND RELATED MATTERS. Investors and securityholders are able to obtain free copies of the Proxy Statement/Prospectus and other documents filed with the SEC by Zymeworks or New Zymeworks through the website maintained by the SEC at www.sec.gov (“EDGAR”). Investors and securityholders are also able to obtain free copies of the Proxy Statement/Prospectus and other documents filed with Canadian securities regulatory authorities by Zymeworks, through the website maintained by the Canadian Securities Administrators at www.sedar.com (“SEDAR”). In addition, investors and securityholders are able to obtain free copies of the documents filed with the SEC and Canadian securities regulatory authorities on Zymeworks’ website at www.zymeworks.com or by contacting Zymeworks’ corporate secretary.
